A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter,Philippe L. Bedard,Eric Chen,Blaise Clarke,Ben Tran,Sebastien J. Hotte,Anastasios Stathis,Hal W. Hirte,Albiruni Ryan Abdul Razak,Michael Reedijk,Zhuo Chen,Brenda Cohen,Wenjiang Zhang,Lisa Wang,S. Percy Ivy,Malcolm J. Moore,Amit M. Oza,Lillian L. Siu,Elaine McWhirter +18 more
TL;DR: Although RO exposure was limited by the presence of autoinduction, RO levels achieved exceeded the area under the concentration-time curve for 0–24 h (AUC0–24) predicted for efficacy in preclinical models using daily dosing.
Journal ArticleDOI
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M. Oza,Ursula A. Matulonis,Susanne Malander,Stacie Hudgens,Jalid Sehouli,Josep M. del Campo,Dominique Berton-Rigaud,Susana Banerjee,Giovanni Scambia,Jonathan S. Berek,Bente Lund,Anna V. Tinker,Felix Hilpert,Isabel Palacio Vázquez,Véronique D'Hondt,Benedict B. Benigno,Diane Provencher,Joseph Buscema,Shefali Agarwal,Mansoor Raza Mirza +19 more
TL;DR: Overall QOL scores remained stable during the treatment and preprogression period in the niraparib group; no significant differences were observed between the nirkarib and placebo group, and pre Progression EQ-5D-5L scores were similar between the two groups in both cohorts.
Journal ArticleDOI
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
S. Y. Cindy Yang,S. Y. Cindy Yang,Stephanie Lheureux,Stephanie Lheureux,Katherine Karakasis,Julia V. Burnier,Jeff Bruce,Derek L. Clouthier,Arnavaz Danesh,Rene Quevedo,Rene Quevedo,Mark Dowar,Youstina Hanna,Tiantian Li,Lin Lu,Wei Xu,Blaise A. Clarke,Blaise A. Clarke,Pamela S. Ohashi,Pamela S. Ohashi,Patricia Shaw,Patricia Shaw,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Amit M. Oza,Amit M. Oza +26 more
TL;DR: An integrated clinical, exome, and transcriptome analysis of 41 primary tumors from LT and ST HGSOC patients suggested that exceptional long- or short-term survival is determined by a concert of clinical, molecular, and microenvironment factors.
Journal ArticleDOI
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
Agustin A. Garcia,Amit M. Oza,H. Hirte,Gini F. Fleming,Denice D. Tsao-Wei,L. Roman,S. Swenson,David R. Gandara,Sidney A. Scudder,Rebecca L. Morgan +9 more
TL;DR: Bev is a recombinant humanized anti-VEGF monoclonal antibody that inhibits the growth of a number of human cancers, including ovarian cancer, and low dose chronic chemotherapy (metrono...
Journal ArticleDOI
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
Helen J. Mackay,Elizabeth Eisenhauer,Suzanne Kamel-Reid,Ming Tsao,Blaise A. Clarke,Katherine Karakasis,Henrica M.J. Werner,Henrica M.J. Werner,Jone Trovik,Jone Trovik,Lars A. Akslen,Lars A. Akslen,Helga B. Salvesen,Helga B. Salvesen,Dongsheng Tu,Amit M. Oza +15 more
TL;DR: The aim of this study was to identify molecular markers associated with mTOR inhibitor activity in women with metastatic endometrial cancer.